These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 22190606)

  • 1. Intracellular and plasma pharmacokinetics of 400 mg of etravirine once daily versus 200 mg of etravirine twice daily in HIV-infected patients.
    Gutiérrez-Valencia A; Martin-Peña R; Torres-Cornejo A; Ruiz-Valderas R; Castillo-Ferrando JR; López-Cortés LF
    J Antimicrob Chemother; 2012 Mar; 67(3):681-4. PubMed ID: 22190606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naive HIV type-1-infected adults.
    DeJesus E; Lalezari JP; Osiyemi OO; Ruane PJ; Ryan R; Kakuda TN; Witek J
    Antivir Ther; 2010; 15(5):711-20. PubMed ID: 20710052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell disposition of raltegravir and newer antiretrovirals in HIV-infected patients: high inter-individual variability in raltegravir cellular penetration.
    Fayet Mello A; Buclin T; Franc C; Colombo S; Cruchon S; Guignard N; Biollaz J; Telenti A; Decosterd LA; Cavassini M
    J Antimicrob Chemother; 2011 Jul; 66(7):1573-81. PubMed ID: 21508009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and pharmacodynamics of etravirine 400 mg once daily in treatment-naïve patients.
    Di Perri G; Green B; Morrish G; Hill A; Faetkenheuer G; Bickel M; van Delft Y; Kurowski M; Kakuda T
    HIV Clin Trials; 2013; 14(3):92-8. PubMed ID: 23835511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic interaction between boceprevir and etravirine in HIV/HCV seronegative volunteers.
    Hammond KP; Wolfe P; Burton JR; Predhomme JA; Ellis CM; Ray ML; Bushman LR; Kiser JJ
    J Acquir Immune Defic Syndr; 2013 Jan; 62(1):67-73. PubMed ID: 23075915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single- and multiple-dose pharmacokinetics of etravirine administered as two different formulations in HIV-1-infected patients.
    Kakuda TN; Schöller-Gyüre M; Workman C; Arasteh K; Pozniak AL; De Smedt G; Beets G; Peeters M; Vandermeulen K; Woodfall BJ; Hoetelmans RM
    Antivir Ther; 2008; 13(5):655-61. PubMed ID: 18771049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and acceptability of once- versus twice-daily lamivudine and abacavir in HIV type-1-infected Ugandan children in the ARROW Trial.
    Musiime V; Kendall L; Bakeera-Kitaka S; Snowden WB; Odongo F; Thomason M; Musoke P; Adkison K; Burger D; Mugyenyi P; Kekitiinwa A; Gibb DM; Walker AS;
    Antivir Ther; 2010; 15(8):1115-24. PubMed ID: 21149918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of elvitegravir and etravirine following coadministration of ritonavir-boosted elvitegravir and etravirine.
    Ramanathan S; Kakuda TN; Mack R; West S; Kearney BP
    Antivir Ther; 2008; 13(8):1011-7. PubMed ID: 19195326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Etravirine concentrations in CSF in HIV-infected patients.
    Tiraboschi JM; Niubo J; Vila A; Perez-Pujol S; Podzamczer D
    J Antimicrob Chemother; 2012 Jun; 67(6):1446-8. PubMed ID: 22357802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of a Clinically Significant Pharmacokinetic Interaction between Etravirine and Raltegravir Using an Original Approach Based on Drug Metabolism, Protein Binding, and Penetration in Seminal Fluid: A Pharmacokinetic Substudy of the ANRS-163 ETRAL Study.
    Lê MP; Valantin MA; Assoumou L; Soulie C; Le Mestre S; Weiss L; Yazdanpanah Y; Molina JM; Bouchaud O; Raffi F; Reynes J; Calvez V; Marcelin AG; Costagliola D; Katlama C; Peytavin G;
    Pharmacotherapy; 2019 Apr; 39(4):514-520. PubMed ID: 30815916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Etravirine has no effect on QT and corrected QT interval in HIV-negative volunteers.
    Peeters M; Janssen K; Kakuda TN; Schöller-Gyüre M; Lachaert R; Hoetelmans RM; Woodfall B; De Smedt G
    Ann Pharmacother; 2008 Jun; 42(6):757-65. PubMed ID: 18445705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects.
    Anderson MS; Kakuda TN; Hanley W; Miller J; Kost JT; Stoltz R; Wenning LA; Stone JA; Hoetelmans RM; Wagner JA; Iwamoto M
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4228-32. PubMed ID: 18838586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of darunavir/cobicistat and etravirine alone and co-administered in HIV-infected patients.
    Moltó J; Curran A; Miranda C; Challenger E; Santos JR; Ribera E; Khoo S; Valle M; Clotet B
    J Antimicrob Chemother; 2018 Mar; 73(3):732-737. PubMed ID: 29237008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and short-term safety and tolerability of etravirine in treatment-experienced HIV-1-infected children and adolescents.
    Königs C; Feiterna-Sperling C; Esposito S; Viscoli C; Rosso R; Kakuda TN; Leemans R; Peeters M; Mack R; Peeters I; Sinha R; Boven K; Giaquinto C
    AIDS; 2012 Feb; 26(4):447-55. PubMed ID: 22156961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and short-term safety of etravirine in combination with fluconazole or voriconazole in HIV-negative volunteers.
    Kakuda TN; Van Solingen-Ristea R; Aharchi F; Smedt GD; Witek J; Nijs S; Vyncke V; Hoetelmans RM
    J Clin Pharmacol; 2013 Jan; 53(1):41-50. PubMed ID: 23400742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of the steady-state pharmacokinetic interaction between etravirine administered as two different formulations and tenofovir disoproxil fumarate in healthy volunteers.
    Kakuda TN; Schöller-Gyüre M; De Smedt G; Beets G; Aharchi F; Peeters MP; Vandermeulen K; Woodfall BJ; Hoetelmans RM
    HIV Med; 2009 Mar; 10(3):173-81. PubMed ID: 19207601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients.
    Garvey L; Latch N; Erlwein OW; Mackie NE; Walsh J; Scullard G; McClure MO; Dickinson L; Back D; Winston A
    Antivir Ther; 2010; 15(2):213-8. PubMed ID: 20386076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absence of circadian variation in the pharmacokinetics of lopinavir/ritonavir given as a once daily dosing regimen in HIV-1-infected patients.
    van Heeswijk RP; Bourbeau M; Seguin I; Giguere P; Garber GE; Cameron DW
    Br J Clin Pharmacol; 2005 Apr; 59(4):398-404. PubMed ID: 15801934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of hepatic impairment on the steady-state pharmacokinetics of etravirine 200 mg BID: an open-label, multiple-dose, controlled Phase I study in adults.
    Schöller-Gyüre M; Kakuda TN; De Smedt G; Woodfall B; Berckmans C; Peeters M; Hoetelmans RM
    Clin Ther; 2010 Feb; 32(2):328-37. PubMed ID: 20206790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and safety of etravirine administered once or twice daily after 2 weeks treatment with efavirenz in healthy volunteers.
    Boffito M; Jackson A; Lamorde M; Back D; Watson V; Taylor J; Waters L; Asboe D; Gazzard B; Pozniak A
    J Acquir Immune Defic Syndr; 2009 Oct; 52(2):222-7. PubMed ID: 19620877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.